Click here to get full coverage on PYXS SEC Filings - Pyxis Oncology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

PYXS SEC Filings - Pyxis Oncology, Inc. 10-K, 10-Q, 8-K Forms  Stock Titan

PYXS SEC Filings - Pyxis Oncology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Click here to get full coverage on Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance

Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know  Yahoo Finance

Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance

Click here to get full coverage on Pyxis Oncology Stock (PYXS) Opinions on Phase 1 Cancer Drug Data | PYXS Stock News - Quiver Quantitative

Pyxis Oncology Stock (PYXS) Opinions on Phase 1 Cancer Drug Data | PYXS Stock News  Quiver Quantitative

Pyxis Oncology Stock (PYXS) Opinions on Phase 1 Cancer Drug Data | PYXS Stock News - Quiver Quantitative

Click here to get full coverage on PYXS: Promising clinical progress for MICVO offset by $79.6M net loss and going concern risks - TradingView

PYXS: Promising clinical progress for MICVO offset by $79.6M net loss and going concern risks  TradingView

PYXS: Promising clinical progress for MICVO offset by $79.6M net loss and going concern risks - TradingView

Click here to get full coverage on Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Nurix Therapeutics (NRIX) and Context Therapeutics (CNTX) - The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Nurix Therapeutics (NRIX) and Context Therapeutics (CNTX)  The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Nurix Therapeutics (NRIX) and Context Therapeutics (CNTX) - The Globe and Mail

Click here to get full coverage on Stifel Nicolaus Lowers Pyxis Oncology (NASDAQ:PYXS) Price Target to $8.00 - MarketBeat

Stifel Nicolaus Lowers Pyxis Oncology (NASDAQ:PYXS) Price Target to $8.00  MarketBeat

Stifel Nicolaus Lowers Pyxis Oncology (NASDAQ:PYXS) Price Target to $8.00 - MarketBeat

Click here to get full coverage on Pyxis Oncology (PYXS) director receives 45,867 stock options at $1.36 strike - Stock Titan

Pyxis Oncology (PYXS) director receives 45,867 stock options at $1.36 strike  Stock Titan

Pyxis Oncology (PYXS) director receives 45,867 stock options at $1.36 strike - Stock Titan

Click here to get full coverage on New Analyst Forecast: $PYXS Given $5 Price Target | PYXS Stock News - Quiver Quantitative

New Analyst Forecast: $PYXS Given $5 Price Target | PYXS Stock News  Quiver Quantitative

New Analyst Forecast: $PYXS Given $5 Price Target | PYXS Stock News - Quiver Quantitative

Click here to get full coverage on Pyxis Oncology, Inc.'s (NASDAQ:PYXS) top owners are retail investors with 39% stake, while 21% is held by institutions - Yahoo Finance

Pyxis Oncology, Inc.'s (NASDAQ:PYXS) top owners are retail investors with 39% stake, while 21% is held by institutions  Yahoo Finance

Pyxis Oncology, Inc.'s (NASDAQ:PYXS) top owners are retail investors with 39% stake, while 21% is held by institutions - Yahoo Finance

Click here to get full coverage on Pyxis Oncology (NASDAQ:PYXS) Posts Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat

Pyxis Oncology (NASDAQ:PYXS) Posts Earnings Results, Beats Expectations By $0.06 EPS  MarketBeat

Pyxis Oncology (NASDAQ:PYXS) Posts Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat

Click here to get full coverage on Pyxis Oncology (PYXS) director sells 15,496 shares under 10b5-1 plan - Stock Titan

Pyxis Oncology (PYXS) director sells 15,496 shares under 10b5-1 plan  Stock Titan

Pyxis Oncology (PYXS) director sells 15,496 shares under 10b5-1 plan - Stock Titan

Click here to get full coverage on We Think Pyxis Oncology (NASDAQ:PYXS) Needs To Drive Business Growth Carefully - Yahoo Finance

We Think Pyxis Oncology (NASDAQ:PYXS) Needs To Drive Business Growth Carefully  Yahoo Finance

We Think Pyxis Oncology (NASDAQ:PYXS) Needs To Drive Business Growth Carefully - Yahoo Finance

Click here to get full coverage on Pyxis fills head and neck cancer study, says cash lasts into Q4 - Stock Titan

Pyxis fills head and neck cancer study, says cash lasts into Q4  Stock Titan

Pyxis fills head and neck cancer study, says cash lasts into Q4 - Stock Titan

Click here to get full coverage on Pyxis Oncology (PYXS) director receives grant of 45,867 stock options - Stock Titan

Pyxis Oncology (PYXS) director receives grant of 45,867 stock options  Stock Titan

Pyxis Oncology (PYXS) director receives grant of 45,867 stock options - Stock Titan

Click here to get full coverage on Pyxis Oncology (PYXS) grants director Jakob Dupont 45,867 stock options - Stock Titan

Pyxis Oncology (PYXS) grants director Jakob Dupont 45,867 stock options  Stock Titan

Pyxis Oncology (PYXS) grants director Jakob Dupont 45,867 stock options - Stock Titan

Click here to get full coverage on Executive at Pyxis Oncology (PYXS) receives new option and RSU equity grants - Stock Titan

Executive at Pyxis Oncology (PYXS) receives new option and RSU equity grants  Stock Titan

Executive at Pyxis Oncology (PYXS) receives new option and RSU equity grants - Stock Titan

Click here to get full coverage on [Form 4] Pyxis Oncology, Inc. Insider Trading Activity - Stock Titan

[Form 4] Pyxis Oncology, Inc. Insider Trading Activity  Stock Titan

[Form 4] Pyxis Oncology, Inc. Insider Trading Activity - Stock Titan

Click here to get full coverage on Cancer drug developer Pyxis taps CEO behind $1.9B Amgen sale - Stock Titan

Cancer drug developer Pyxis taps CEO behind $1.9B Amgen sale  Stock Titan

Cancer drug developer Pyxis taps CEO behind $1.9B Amgen sale - Stock Titan

Click here to get full coverage on Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - Stock Titan

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets  Stock Titan

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - Stock Titan

Click here to get full coverage on Pyxis Oncology Stock Slides 73% With A 7-Day Losing Spree - Trefis

Pyxis Oncology Stock Slides 73% With A 7-Day Losing Spree  Trefis

Pyxis Oncology Stock Slides 73% With A 7-Day Losing Spree - Trefis

Click here to get full coverage on Would You Still Hold Pyxis Oncology Stock If It Fell Another 30%? - Trefis

Would You Still Hold Pyxis Oncology Stock If It Fell Another 30%?  Trefis

Would You Still Hold Pyxis Oncology Stock If It Fell Another 30%? - Trefis

Click here to get full coverage on Pyxis Oncology Stock 6-Day Losing Spree: Stock Falls 71% - Trefis

Pyxis Oncology Stock 6-Day Losing Spree: Stock Falls 71%  Trefis

Pyxis Oncology Stock 6-Day Losing Spree: Stock Falls 71% - Trefis

Click here to get full coverage on Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Moderate Buy" from Analysts  MarketBeat

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Click here to get full coverage on Analysts Sound Alarm On Pyxis Oncology's Tiny Trial - Benzinga

Analysts Sound Alarm On Pyxis Oncology's Tiny Trial  Benzinga

Analysts Sound Alarm On Pyxis Oncology's Tiny Trial - Benzinga

Click here to get full coverage on ctDNA reduction in 37 clinical samples: Pyxis Oncology presents MICVO translational findings at ESMO & AACR 2025 - Stock Titan

ctDNA reduction in 37 clinical samples: Pyxis Oncology presents MICVO translational findings at ESMO & AACR 2025  Stock Titan

ctDNA reduction in 37 clinical samples: Pyxis Oncology presents MICVO translational findings at ESMO & AACR 2025 - Stock Titan

Click here to get full coverage on Pyxis Oncology: Readouts Ahead, Although Cash Might Dwindle (Rating Downgrade) (NASDAQ:PYXS) - Seeking Alpha

Pyxis Oncology: Readouts Ahead, Although Cash Might Dwindle (Rating Downgrade) (NASDAQ:PYXS)  Seeking Alpha

Pyxis Oncology: Readouts Ahead, Although Cash Might Dwindle (Rating Downgrade) (NASDAQ:PYXS) - Seeking Alpha

Click here to get full coverage on Pyxis Oncology stock plummets after early-stage cancer drug data - Investing.com

Pyxis Oncology stock plummets after early-stage cancer drug data  Investing.com

Pyxis Oncology stock plummets after early-stage cancer drug data - Investing.com

Click here to get full coverage on Pyxis Oncology Stock Plunge: A Buy Signal? - StocksToTrade

Pyxis Oncology Stock Plunge: A Buy Signal?  StocksToTrade

Pyxis Oncology Stock Plunge: A Buy Signal? - StocksToTrade

Click here to get full coverage on Pyxis Oncology, Inc. Announces Positive Preliminary Phase 1 Data for MICVO - TradingView

Pyxis Oncology, Inc. Announces Positive Preliminary Phase 1 Data for MICVO  TradingView

Pyxis Oncology, Inc. Announces Positive Preliminary Phase 1 Data for MICVO - TradingView

Click here to get full coverage on Pyxis Oncology stock price target raised to $7 by H.C. Wainwright - Investing.com

Pyxis Oncology stock price target raised to $7 by H.C. Wainwright  Investing.com

Pyxis Oncology stock price target raised to $7 by H.C. Wainwright - Investing.com

Click here to get full coverage on Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation - simplywall.st

Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation  simplywall.st

Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation - simplywall.st

Click here to get full coverage on Pyxis Oncology: MICVO Data Could Be The Tipping Point In 2025 - RTTNews

Pyxis Oncology: MICVO Data Could Be The Tipping Point In 2025  RTTNews

Pyxis Oncology: MICVO Data Could Be The Tipping Point In 2025 - RTTNews

Click here to get full coverage on Pyxis’s Cancer Bet Has Paid Off So Far - Finimize

Pyxis’s Cancer Bet Has Paid Off So Far  Finimize

Pyxis’s Cancer Bet Has Paid Off So Far - Finimize

Click here to get full coverage on PYXS: MCVO shows high response rates and promising safety in head and neck cancer, with pivotal trials planned - TradingView

PYXS: MCVO shows high response rates and promising safety in head and neck cancer, with pivotal trials planned  TradingView

PYXS: MCVO shows high response rates and promising safety in head and neck cancer, with pivotal trials planned - TradingView

Click here to get full coverage on A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $5 to $7 - 富途牛牛

A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $5 to $7  富途牛牛

A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $5 to $7 - 富途牛牛

Click here to get full coverage on Pyxis Oncology Stock: Can PYXS Survive the Cash Burn And Delisting Risk? - AD HOC NEWS

Pyxis Oncology Stock: Can PYXS Survive the Cash Burn And Delisting Risk?  AD HOC NEWS

Pyxis Oncology Stock: Can PYXS Survive the Cash Burn And Delisting Risk? - AD HOC NEWS

Click here to get full coverage on Pyxis Oncology And 2 Other Promising Penny Stocks To Watch - Yahoo Finance

Pyxis Oncology And 2 Other Promising Penny Stocks To Watch  Yahoo Finance

Pyxis Oncology And 2 Other Promising Penny Stocks To Watch - Yahoo Finance

Click here to get full coverage on Portfolio Shifts: Can PYXS sustain earnings growth - Global Markets & Weekly High Return Opportunities - baoquankhu1.vn

Portfolio Shifts: Can PYXS sustain earnings growth - Global Markets & Weekly High Return Opportunities  baoquankhu1.vn

Portfolio Shifts: Can PYXS sustain earnings growth - Global Markets & Weekly High Return Opportunities - baoquankhu1.vn

Click here to get full coverage on Pyxis Oncology (PYXS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $PYXS - MarketBeat

Pyxis Oncology (PYXS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $PYXS  MarketBeat

Pyxis Oncology (PYXS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $PYXS - MarketBeat

Click here to get full coverage on Pyxis Oncology Reports Q4 Results, Advances MICVO Program - TipRanks

Pyxis Oncology Reports Q4 Results, Advances MICVO Program  TipRanks

Pyxis Oncology Reports Q4 Results, Advances MICVO Program - TipRanks

Click here to get full coverage on William Blair reiterates Pyxis Oncology stock rating on trial pace - Investing.com

William Blair reiterates Pyxis Oncology stock rating on trial pace  Investing.com

William Blair reiterates Pyxis Oncology stock rating on trial pace - Investing.com

Click here to get full coverage on Guggenheim reiterates Buy on Pyxis Oncology stock ahead of trial data - Investing.com

Guggenheim reiterates Buy on Pyxis Oncology stock ahead of trial data  Investing.com

Guggenheim reiterates Buy on Pyxis Oncology stock ahead of trial data - Investing.com

Click here to get full coverage on Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results - Yahoo Finance

Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results  Yahoo Finance

Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results - Yahoo Finance

Click here to get full coverage on Pyxis Oncology Insiders Lose Out As Stock Sinks To US$1.14 - Yahoo Finance

Pyxis Oncology Insiders Lose Out As Stock Sinks To US$1.14  Yahoo Finance

Pyxis Oncology Insiders Lose Out As Stock Sinks To US$1.14 - Yahoo Finance

Click here to get full coverage on Jefferies raises Pyxis Oncology stock price target on drug data - Investing.com

Jefferies raises Pyxis Oncology stock price target on drug data  Investing.com

Jefferies raises Pyxis Oncology stock price target on drug data - Investing.com

Click here to get full coverage on Pyxis Oncology director Humphrey sells $15917 in shares - Investing.com

Pyxis Oncology director Humphrey sells $15917 in shares  Investing.com

Pyxis Oncology director Humphrey sells $15917 in shares - Investing.com

Click here to get full coverage on Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - Yahoo Finance

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets  Yahoo Finance

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - Yahoo Finance

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on Pyxis Oncology announces retirement of CFO and COO Pamela Connealy - Investing.com

Pyxis Oncology announces retirement of CFO and COO Pamela Connealy  Investing.com

Pyxis Oncology announces retirement of CFO and COO Pamela Connealy - Investing.com

Click here to get full coverage on Pyxis Oncology director Humphrey sells $15917 in shares By Investing.com - Investing.com South Africa

Pyxis Oncology director Humphrey sells $15917 in shares By Investing.com  Investing.com South Africa

Pyxis Oncology director Humphrey sells $15917 in shares By Investing.com - Investing.com South Africa

Click here to get full coverage on PYXS Stock Price, News & Analysis - Stock Titan

PYXS Stock Price, News & Analysis  Stock Titan

PYXS Stock Price, News & Analysis - Stock Titan

Click here to get full coverage on Pyxis Oncology director Humphrey sells $15917 in shares By Investing.com - Investing.com Australia

Pyxis Oncology director Humphrey sells $15917 in shares By Investing.com  Investing.com Australia

Pyxis Oncology director Humphrey sells $15917 in shares By Investing.com - Investing.com Australia

Click here to get full coverage on H.C. Wainwright reiterates Buy on Pyxis Oncology stock, $7 target By Investing.com - Investing.com India

H.C. Wainwright reiterates Buy on Pyxis Oncology stock, $7 target By Investing.com  Investing.com India

H.C. Wainwright reiterates Buy on Pyxis Oncology stock, $7 target By Investing.com - Investing.com India

Click here to get full coverage on Guggenheim reiterates Buy on Pyxis Oncology stock ahead of trial data - Investing.com Canada

Guggenheim reiterates Buy on Pyxis Oncology stock ahead of trial data  Investing.com Canada

Guggenheim reiterates Buy on Pyxis Oncology stock ahead of trial data - Investing.com Canada

Click here to get full coverage on FDA Grants Fast Track Designation to PYX-201 for Recurrent/Metastatic HNSCC - OncLive

FDA Grants Fast Track Designation to PYX-201 for Recurrent/Metastatic HNSCC  OncLive

FDA Grants Fast Track Designation to PYX-201 for Recurrent/Metastatic HNSCC - OncLive

Click here to get full coverage on William Blair reiterates Pyxis Oncology stock rating on trial pace By Investing.com - Investing.com UK

William Blair reiterates Pyxis Oncology stock rating on trial pace By Investing.com  Investing.com UK

William Blair reiterates Pyxis Oncology stock rating on trial pace By Investing.com - Investing.com UK

Click here to get full coverage on PYX-201 Generates Responses in Pretreated Advanced HNSCC and Other Solid Tumors - OncLive

PYX-201 Generates Responses in Pretreated Advanced HNSCC and Other Solid Tumors  OncLive

PYX-201 Generates Responses in Pretreated Advanced HNSCC and Other Solid Tumors - OncLive

Click here to get full coverage on Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity - The Manila Times

Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity  The Manila Times

Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity - The Manila Times

Click here to get full coverage on What is the current Price Target and Forecast for Pyxis Oncology (PYXS) - Zacks Investment Research

What is the current Price Target and Forecast for Pyxis Oncology (PYXS)  Zacks Investment Research

What is the current Price Target and Forecast for Pyxis Oncology (PYXS) - Zacks Investment Research

Click here to get full coverage on Pyxis Oncology Stock Price Forecast. Should You Buy PYXS? - StockInvest.us

Pyxis Oncology Stock Price Forecast. Should You Buy PYXS?  StockInvest.us

Pyxis Oncology Stock Price Forecast. Should You Buy PYXS? - StockInvest.us

Click here to get full coverage on Ken Kobayashi Net Worth (2026) - GuruFocus

Ken Kobayashi Net Worth (2026)  GuruFocus

Ken Kobayashi Net Worth (2026) - GuruFocus

Click here to get full coverage on Pyxis Oncology (PYXS) Stock Forecast and Price Target 2026 $PYXS - MarketBeat

Pyxis Oncology (PYXS) Stock Forecast and Price Target 2026 $PYXS  MarketBeat

Pyxis Oncology (PYXS) Stock Forecast and Price Target 2026 $PYXS - MarketBeat

Click here to get full coverage on PYXS Stock Price and Chart — NASDAQ:PYXS - TradingView

PYXS Stock Price and Chart — NASDAQ:PYXS  TradingView

PYXS Stock Price and Chart — NASDAQ:PYXS - TradingView

Click here to get full coverage on EX-99.1 - SEC.gov

EX-99.1 - SEC.gov

Click here to get full coverage on Pyxis Oncology (PYXS) - Zacks Investment Research

Pyxis Oncology (PYXS)  Zacks Investment Research

Pyxis Oncology (PYXS) - Zacks Investment Research

Click here to get full coverage on PYXS Forecast — Price Target — Prediction for 2027 - TradingView

PYXS Forecast — Price Target — Prediction for 2027  TradingView

PYXS Forecast — Price Target — Prediction for 2027 - TradingView

Click here to get full coverage on FDA grants fast track status to Pyxis’ PYX-201 - Pharmaceutical Technology

FDA grants fast track status to Pyxis’ PYX-201  Pharmaceutical Technology

FDA grants fast track status to Pyxis’ PYX-201 - Pharmaceutical Technology

Click here to get full coverage on Pyxis Oncology: Promising Research Amid Cash Constraints (NASDAQ:PYXS) - Seeking Alpha

Pyxis Oncology: Promising Research Amid Cash Constraints (NASDAQ:PYXS)  Seeking Alpha

PYXS

Price Chart

Key Statistics

Technicals

About PYXS

Latest News

PYXS SEC Filings - Pyxis Oncology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance

Pyxis Oncology Stock (PYXS) Opinions on Phase 1 Cancer Drug Data | PYXS Stock News - Quiver Quantitative

Advanced Charts

Top Gainers

Top Losers